AD-208

DRUG2 trials

Sponsors

Addpharma Inc.

Conditions

Androgenetic Alopecia

Phase 1

To Evaluate the Pharmacokinetics and Safety of AD-208

CompletedNCT04214808

Addpharma Inc.Androgenetic Alopecia

Start: 2020-01-03End: 2020-05-04Updated: 2020-12-02

Phase 3

A Study to Evaluate the Efficacy and Safety of AD-208

CompletedNCT04825561

Addpharma Inc.Androgenetic Alopecia

Start: 2021-06-09End: 2023-06-01Updated: 2023-07-21

Related Papers

Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial.

2025-08-01